Cargando…

519. Immune responses and COVID-19 severity

BACKGROUND: The coronavirus-19-disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to >200 countries and surpassed 7 million cases. There is a broad range of COVID-19 illness, ranging from milder disease to a rapidly progressive respir...

Descripción completa

Detalles Bibliográficos
Autores principales: salvatore, mirella, Vorkas, Charles K, Sing, Harjot, Morales, Ayana, Soave, Rosemary, Kapatia, Shashi, Ellsworth, Grant, Saito, Kotha, Brown, Christopher D, Hsu, Jing-Mei, Casano, Joseph, Inghirami, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776417/
http://dx.doi.org/10.1093/ofid/ofaa439.713
_version_ 1783630678312615936
author salvatore, mirella
Vorkas, Charles K
Sing, Harjot
Morales, Ayana
Soave, Rosemary
Kapatia, Shashi
Ellsworth, Grant
Saito, Kotha
Brown, Christopher D
Hsu, Jing-Mei
Casano, Joseph
Inghirami, Giorgio
author_facet salvatore, mirella
Vorkas, Charles K
Sing, Harjot
Morales, Ayana
Soave, Rosemary
Kapatia, Shashi
Ellsworth, Grant
Saito, Kotha
Brown, Christopher D
Hsu, Jing-Mei
Casano, Joseph
Inghirami, Giorgio
author_sort salvatore, mirella
collection PubMed
description BACKGROUND: The coronavirus-19-disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to >200 countries and surpassed 7 million cases. There is a broad range of COVID-19 illness, ranging from milder disease to a rapidly progressive respiratory disease and ARDS. The causes of this different clinical course and the drivers for severe disease are currently unknown. A fulminant increase of pro-inflammatory cytokines is thought to play a role in causing a rapid disease evolution, however the immune correlates of severe COVID-19 remain unclear. METHODS: To gain insight into relationship between immune responses and disease severity we built a longitudinal cohort of 40 adult patients with known COVID-19. Samples were collected at diagnosis and every 7 days until hospital discharge or death. As controls we also included a group of convalescent patients, and subjects who tested negative for COVID-19 by PCR. Clinical and laboratory data and were also collected. Multicolor flow cytometry was used to determine the presence and phenotype of B, T and natural killer (NK) cells. We also identified specific sub-populations (Tfh, activated/cytotoxic CD8 and NK) and assessed lymphoid exhaustion of different cell types such as naïve, memory T cells, or NK over time. Anti-Sars-CoV2 IgG and IgM antibody were detected using lateral flow method. RESULTS: We found that the absolute number of lymphocytes and monocytes was decreased starting at diagnosis and correlated with disease severity. Disease severity correlated with decreased NK and T cell. In severe COVID-19 cases, NK cell populations were strongly decreased over time in intubated patients while they recovered in patients who improved and were discharged. CD8+ were also decreased at disease onset and seemed to correlate with disease severity. A high percentage of CD4+ and CD8+ T cells showed an exhausted phenotype. All patients tested at admission had IgM antibody responses irrespective of the course of the disease. Further analyses are ongoing. CONCLUSION: The characterization and role of the immune responses in COVID-19 evolution is still under investigation. Further characterization of viral and immune factors will help in identifying subjects at high risk of severe disease and targets for intervention. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776417
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77764172021-01-07 519. Immune responses and COVID-19 severity salvatore, mirella Vorkas, Charles K Sing, Harjot Morales, Ayana Soave, Rosemary Kapatia, Shashi Ellsworth, Grant Saito, Kotha Brown, Christopher D Hsu, Jing-Mei Casano, Joseph Inghirami, Giorgio Open Forum Infect Dis Poster Abstracts BACKGROUND: The coronavirus-19-disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to >200 countries and surpassed 7 million cases. There is a broad range of COVID-19 illness, ranging from milder disease to a rapidly progressive respiratory disease and ARDS. The causes of this different clinical course and the drivers for severe disease are currently unknown. A fulminant increase of pro-inflammatory cytokines is thought to play a role in causing a rapid disease evolution, however the immune correlates of severe COVID-19 remain unclear. METHODS: To gain insight into relationship between immune responses and disease severity we built a longitudinal cohort of 40 adult patients with known COVID-19. Samples were collected at diagnosis and every 7 days until hospital discharge or death. As controls we also included a group of convalescent patients, and subjects who tested negative for COVID-19 by PCR. Clinical and laboratory data and were also collected. Multicolor flow cytometry was used to determine the presence and phenotype of B, T and natural killer (NK) cells. We also identified specific sub-populations (Tfh, activated/cytotoxic CD8 and NK) and assessed lymphoid exhaustion of different cell types such as naïve, memory T cells, or NK over time. Anti-Sars-CoV2 IgG and IgM antibody were detected using lateral flow method. RESULTS: We found that the absolute number of lymphocytes and monocytes was decreased starting at diagnosis and correlated with disease severity. Disease severity correlated with decreased NK and T cell. In severe COVID-19 cases, NK cell populations were strongly decreased over time in intubated patients while they recovered in patients who improved and were discharged. CD8+ were also decreased at disease onset and seemed to correlate with disease severity. A high percentage of CD4+ and CD8+ T cells showed an exhausted phenotype. All patients tested at admission had IgM antibody responses irrespective of the course of the disease. Further analyses are ongoing. CONCLUSION: The characterization and role of the immune responses in COVID-19 evolution is still under investigation. Further characterization of viral and immune factors will help in identifying subjects at high risk of severe disease and targets for intervention. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776417/ http://dx.doi.org/10.1093/ofid/ofaa439.713 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
salvatore, mirella
Vorkas, Charles K
Sing, Harjot
Morales, Ayana
Soave, Rosemary
Kapatia, Shashi
Ellsworth, Grant
Saito, Kotha
Brown, Christopher D
Hsu, Jing-Mei
Casano, Joseph
Inghirami, Giorgio
519. Immune responses and COVID-19 severity
title 519. Immune responses and COVID-19 severity
title_full 519. Immune responses and COVID-19 severity
title_fullStr 519. Immune responses and COVID-19 severity
title_full_unstemmed 519. Immune responses and COVID-19 severity
title_short 519. Immune responses and COVID-19 severity
title_sort 519. immune responses and covid-19 severity
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776417/
http://dx.doi.org/10.1093/ofid/ofaa439.713
work_keys_str_mv AT salvatoremirella 519immuneresponsesandcovid19severity
AT vorkascharlesk 519immuneresponsesandcovid19severity
AT singharjot 519immuneresponsesandcovid19severity
AT moralesayana 519immuneresponsesandcovid19severity
AT soaverosemary 519immuneresponsesandcovid19severity
AT kapatiashashi 519immuneresponsesandcovid19severity
AT ellsworthgrant 519immuneresponsesandcovid19severity
AT saitokotha 519immuneresponsesandcovid19severity
AT brownchristopherd 519immuneresponsesandcovid19severity
AT hsujingmei 519immuneresponsesandcovid19severity
AT casanojoseph 519immuneresponsesandcovid19severity
AT inghiramigiorgio 519immuneresponsesandcovid19severity